New Delivery Systems for Intranasal Lipopeptide-based Vaccine against Group A Streptococcus

• In: Short Communications B3 on Tuesday, 23 May 2017, 11:15-12:30
• At: Stockholm (Sweden) (2017)
• Type: Presentation
• By: SKWARCYNZKSI, Mariusz (Brisbane, Australia)
• Co-author(s): Mariusz Skwarczynski: School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Australia
  Nirmal Marasini: School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Australia
  Khairunnisa Abdul Ghaffar: School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Australia
  Ashwini Kumar Giddam: School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Australia
  Michael R. Batzloff: Institute for Glycomics, Griffith University, Gold Coast, Australia
  Michael F. Good: Institute for Glycomics, Griffith University, Gold Coast, Australia
  Istvan Toth: School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Australia;Pharmacy Australia Centre of Excellence, The University of Queensland, Woolloongabba, Australia;Institute for Molecular Bioscience, The University of Queensland, St Lucia, Australia
  
• Abstract:

  Backgrounds

  An intranasal delivery of vaccines is one of the most preferable routes of administration. Induction of mucosal immunity by Group A streptococcus (GAS) vaccine is highly preferable as the first step of GAS infection is typically following throat (mucosal) colonization. 

  Aims

  The purpose of this study was to develop intranasal

  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login